{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:46:43Z","timestamp":1791013603764,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.euroneuro.2006.04.005","type":"journal-article","created":{"date-parts":[[2006,6,11]],"date-time":"2006-06-11T13:58:40Z","timestamp":1150034320000},"page":"S128-S133","source":"Crossref","is-referenced-by-count":100,"special_numbering":"S2","title":["Pregabalin: From molecule to medicine"],"prefix":"10.1016","volume":"16","author":[{"given":"Richard","family":"Kavoussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2006.04.005_bib1","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.euroneuro.2006.04.004","article-title":"Therapeutic options: addressing the current dilemma","volume":"16S2","author":"Dinan","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.04.005_bib2","first-page":"1086","article-title":"Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gapapentin and pregabalin","volume":"295","author":"Dooley","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2006.04.005_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/10673229809000328","article-title":"Antidepressant-induced sexual dysfunction: review, classification, and suggestions for treatment","volume":"6","author":"Ellison","year":"1998","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.005_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0304-3959(03)00173-8","article-title":"Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C","volume":"105","author":"Fehrenbacher","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.euroneuro.2006.04.005_bib5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.jcp.0000084032.22282.ff","article-title":"A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder","volume":"23","author":"Feltner","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.04.005_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0703794","article-title":"Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity","volume":"132","author":"Field","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl. 8","key":"10.1016\/j.euroneuro.2006.04.005_bib7","first-page":"93S","article-title":"Pregabalin's speed of onset in generalized anxiety disorder","volume":"55","author":"Fieve","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.005_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0922-4106(93)90156-4","article-title":"Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies","volume":"244","author":"Hill","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2006.04.005_bib9","first-page":"1","article-title":"Evaluation of the cognitive and psychomotor profile of pregabalin compared to alprazolam in normal volunteers","volume":"5","author":"Hindmarch","year":"2002","journal-title":"Int. J. Neuropsychopharm."},{"issue":"Suppl. 3","key":"10.1016\/j.euroneuro.2006.04.005_bib10","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1016\/S0924-977X(02)80535-1","article-title":"A placebo-controlled study of pregabalin and venlafaxine treatment of GAD","volume":"12","author":"Kasper","year":"2002","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.04.005_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.4088\/JCP.v61n0406","article-title":"Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine","volume":"61","author":"Kennedy","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.005_bib12","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0006-3223(02)01672-4","article-title":"Molecular targets in the treatment of anxiety","volume":"52","author":"Kent","year":"2002","journal-title":"Biol. Psychiatry"},{"issue":"Pt. 1","key":"10.1016\/j.euroneuro.2006.04.005_bib13","first-page":"1319","article-title":"Anxiolytic-like effects of pregabalin","volume":"25","author":"Kinsora","year":"1999","journal-title":"Soc. Neurosci."},{"issue":"Suppl. 6","key":"10.1016\/j.euroneuro.2006.04.005_bib14","doi-asserted-by":"crossref","first-page":"S399","DOI":"10.1016\/S0924-977X(99)00051-6","article-title":"Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?","volume":"9","author":"Lader","year":"1999","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.04.005_bib15","series-title":"2002 Abstract Viewer and Itinerary Planner","article-title":"Characterization of the anxiolytic-like activity and side effects of pregabalin in mice","author":"Lotarski","year":"2002"},{"issue":"Suppl. 4","key":"10.1016\/j.euroneuro.2006.04.005_bib16","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1016\/S0924-977X(03)92175-4","article-title":"The efficacy of pregabalin in treating psychic and somatic symptoms in generalized anxiety disorder (GAD)","volume":"13","author":"Lydiard","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.04.005_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0301-0082(03)00087-X","article-title":"The neurobiology and control of anxious states","volume":"70","author":"Millan","year":"2003","journal-title":"Prog. Neurobiol."},{"issue":"Suppl. 4","key":"10.1016\/j.euroneuro.2006.04.005_bib18","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/S0924-977X(03)92174-2","article-title":"Pregabalin in generalized anxiety disorder: speed of onset","volume":"13","author":"Montgomery","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"Suppl. 22","key":"10.1016\/j.euroneuro.2006.04.005_bib19","first-page":"12","article-title":"The functional anatomy, neurochemistry, and pharmacology of anxiety","volume":"60","author":"Ninan","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.005_bib20","article-title":"Pregabalin treatment of GAD","author":"Pande","year":"2000"},{"key":"10.1016\/j.euroneuro.2006.04.005_bib21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","article-title":"Pregabalin in generalized anxiety disorder: a placebo-controlled trial","volume":"160","author":"Pande","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.005_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.jcp.0000155820.74832.b0","article-title":"Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing","volume":"25","author":"Pohl","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.04.005_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00004714-200002000-00004","article-title":"A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder","volume":"20","author":"Rickels","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.04.005_bib24","first-page":"1","article-title":"Efficacy and safety of pregabalin and alprazolam in generalized anxiety disorder","volume":"5","author":"Rickels","year":"2002","journal-title":"Int. J. Neuropsychopharm."},{"key":"10.1016\/j.euroneuro.2006.04.005_bib25","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199305133281907","article-title":"Use of benzodiazepines in anxiety disorders","volume":"328","author":"Shader","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2006.04.005_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1476-5381.1991.tb12413.x","article-title":"The behavioural properties of CI-988, a selective cholecystokinin B receptor antagonist","volume":"104","author":"Singh","year":"1991","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl. 3","key":"10.1016\/j.euroneuro.2006.04.005_bib27","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1016\/S0924-977X(02)80555-7","article-title":"Pregabalin in generalized anxiety disorder: long term efficacy and relapse prevention","volume":"12","author":"Smith","year":"2002","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.04.005_bib28","doi-asserted-by":"crossref","first-page":"460","DOI":"10.4088\/JCP.v65n0401","article-title":"Anticonvulsants as anxiolytics: Part 2. Pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels","volume":"65","author":"Stahl","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.005_bib29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1527-3458.2004.tb00012.x","article-title":"The biology and pharmacology of calcium channel \u03b12\u2013\u03b4 proteins: Pfizer Satellite Symposium to the 2003 Society for Neuroscience Meeting, Sheraton New Orleans Hotel, New Orleans, LA, November 10, 2003","volume":"10","author":"Taylor","year":"2004","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.euroneuro.2006.04.005_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00403989","article-title":"A simple and reliable conflict procedure for testing anti-anxiety agents","volume":"21","author":"Vogel","year":"1971","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.euroneuro.2006.04.005_bib31","first-page":"151","article-title":"Benzodiazepines: use, abuse, and consequences","volume":"44","author":"Woods","year":"1992","journal-title":"Pharmacol. Rev."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X06000733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X06000733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T22:54:13Z","timestamp":1547592853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X06000733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":31,"alternative-id":["S0924977X06000733"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2006.04.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}